30 closest matches · ranked by relevance
EBV-Related Post-Transplant Lymphoproliferative Disorder · Monomorphic Post-Transplant Lymphoproliferative Disorder · Polymorphic Post-Transplant Lymphoproliferative Disorder
Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…
Post-transplant Lymphoproliferative Disease · Solid Organ Transplant · Stem Cell Transplant (Bone Marrow Transplant)
Primary: Overall Response Rate — 3 Participants
Lymphoproliferative Disorder
Primary: Event-free Survival — 71 percentage of participants analyzed
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute · Leukemia, Myelocytic, Chronic
Primary: Overall Recipient Survival at 6-month Post-relapse of Disease — 0; 4 participants
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Complete Remission Rate — 8; 6 Participants
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Recurrent Adult Acute Lymphoblastic Leukemia · Recurrent Adult Acute Myeloid Leukemia
Primary: Safety of DLI Following a Non-myeloablative Transplant, Defined as Incidence of Grade IV Acute GVHD — 5.7 percentage of participants
Hodgkin's Disease · Leukemia · Myelodysplastic Syndrome
Primary: Safety of Rituximab Prophylaxis — 23 participants
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Chronic Lymphocytic Leukemia
Primary: Percentage Patients With an Increase of at Least 10 Percentage Points in Donor T-cell Chimerism — 60; 30; 33.3 percentage of participants
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Lymphoma, Large Cell, Diffuse · Lymphoma, Mixed Cell, Diffuse · Primary Mediastinal Large B-Cell Lymphoma
Primary: Progression-free Survival — 72 Percent
Non-Hodgkin's Lymphoma · Diffuse Large Cell Lymphoma · Mantle Cell Lymphoma
Primary: Event-free Survival (EFS) — 83 percentage of not experiencing EFS event
Non-hodgkin Lymphoma · Hodgkin Lymphoma
Primary: To Compare 2-year Overall Survival of Patients With Lymphoma Undergoing RIC SCT Between Those Receiving Tacrolimus/Sirolimus/Methotrexate and Those Receiving…
Non-Hodgkin's Lymphoma · Hodgkins Disease
Primary: Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT) — 4; 12 Participants
B-cell Adult Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia · B-cell Chronic Lymphocytic Leukemia
Primary: Disease Relapse Rate — 18 Participants
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 68.0; 50.0; 16.0; 14.3 Percentage of participants
Diffuse, Large B-Cell, Lymphoma · Lymphoma, Low-Grade · T-Cell Lymphoma
Primary: Peripheral Blood All-cell Donor Chimerism — 95 percentage of donor-derived elements
Acute Myelogenous Leukemia · Acute Lymphoid Leukemia · Juvenile Myelomonocytic Leukemia
Primary: Relapse Rate — 23.5 percentage of participants
Prolymphocytic Leukemia · Recurrent Adult Hodgkin Lymphoma · Recurrent Childhood Hodgkin Lymphoma
Primary: Engraftment of HLA Identical PBSC Allografts — 53 Participants
Leukemia · Lymphoma
Primary: 2-year Progression-free Survival in Early Disease Participants — 79.5 percentage of participants
Lung Transplant
Primary: Earliest Time to Any of the Following Events: Chronic Allograft Dysfunction, Listed for Retransplant or Death — NA; 703 Days — p=0.514
Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Overall Response Rate — 1; 1; 3; 1 Participants
Blood Cancer · Leukemia
Primary: Acute Graft vs Host Disease (GvHD) — 2.7 percentage of participants
Blastoid Variant Mantle Cell Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Follicular Lymphoma
Primary: Progression Free Survival Probability at 12-month Post HCT — 0.80 probability
Graft Versus Host Disease · GVHD
Primary: Incidence of Grade II-IV Acute GVHD (aGVHD) Developing by Day 100 Following Non-myeloablative PBSC Transplantation Using Tacrolimus and Sirolimus. — 5 participants
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
Acute Myeloid Leukemia · B-Cell Non-Hodgkin Lymphoma · Chronic Lymphocytic Leukemia
Primary: Full-dose Donor Chimerism (FDC) — 12 Participants
Recurrent Lymphoproliferative Disorder · Refractory Lymphoproliferative Disorder
Primary: Overall Response Rate — 0 percentage of participants
Hodgkin's Lymphoma · Lymphoid Leukemia · Lymphoma
Primary: The Number of Patients With Relapse-free/Donor Lymphocyte Infusion(DLI)-Free Survival Rates Between Patients Randomized to MMF-30 (Control Cohort) and MMF-15…
Lymphoma
Primary: Progression-free Survival at 1 Year — 33.3 proportion of progression-free pts